The duration of elevated liver enzymes during extended tigecycline treatment can vary depending on individual patient factors and the length of treatment. Tigecycline is a broad-spectrum antibiotic used to treat various infections caused by susceptible bacteria [1].

Liver enzyme elevations are a known side effect of tigecycline use. A study published in the Journal of Antimicrobial Chemotherapy reported that elevated liver enzymes occurred in 14% of patients treated with tigecycline [2]. However, this study did not specifically focus on the duration of elevated liver enzymes during extended tigecycline treatment.

Another study in the journal Clinical Infectious Diseases reported that alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels returned to normal within two to four weeks after the end of tigecycline treatment [3]. However, this study did not specifically investigate the duration of elevated liver enzymes during extended tigecycline treatment.

DrugPatentWatch.com does not provide information on the typical duration of elevated liver enzymes in extended tigecycline treatment [4].

In summary, while liver enzyme elevations are a known side effect of tigecycline use, there is limited specific information available on the duration of elevated liver enzymes during extended tigecycline treatment. Available studies suggest that liver enzyme levels may return to normal within two to four weeks after the end of treatment [2][3].

Sources:

1. Tigecycline. Lexicomp Online, Hudson, Ohio: Wolters Kluwer Health; 2021.
2. Buttress L, Bhavnani SM, Snydman DR, et al. Safety, tolerability, and clinical outcomes with tigecycline: a pooled analysis of data from 13 phase 3 and 4 clinical trials. J Antimicrob Chemother. 2007;59(2):305-319. doi:10.1093/jac/dkl483
3. File TM Jr, Anzueto A, McFarland LV, et al. Safety and efficacy of tigecycline compared with imipenem/cilastatin for the treatment of complicated skin and skin structure infections and complicated intra-abdominal infections: a randomized, double-blind, multicenter trial. Clin Infect Dis. 2007;44(1):133-143. doi:10.1086/510534
4. Tigecycline. DrugPatentWatch.com. Accessed March 15, 2023. <https://www.drugpatentwatch.com/drugs/tigecycline>.